104255-56-3

Basic information

• Product Name: 4H-1,4-Benzoxazin-4-amine,2,3-dihydro-(9CI)
• Synonyms: 4H-1,4-Benzoxazin-4-amine,2,3-dihydro-(9CI);2H-benzo[b][1,4]oxazin-4(3H)-amine;4H-1,4-Benzoxazin-4-aMine, 2,3-dihydro-;2,3-Dihydro-4H-1,4-benzoxazin-4-amine;3,4-Dihydro-2H-1,4-benzoxazin-4-aMine
• CAS NO: 104255-56-3
• Molecular Formula: C₈H₁₀N₂O
• Molecular Weight: 150.18
• Product Categories: AMINEPRIMARY
• Mol File: 104255-56-3.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 277℃
• Flash Point: 121℃
• Appearance: /
• Density: 1.192
• Vapor Pressure: 0.005mmHg at 25°C
• Refractive Index: 1.591
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4H-1,4-Benzoxazin-4-amine,2,3-dihydro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-1,4-Benzoxazin-4-amine,2,3-dihydro-(9CI)(104255-56-3)
• EPA Substance Registry System: 4H-1,4-Benzoxazin-4-amine,2,3-dihydro-(9CI)(104255-56-3)

Safety Data

• Hazardous Substances Data: 104255-56-3(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H10N2O/c9-10-5-6-11-8-4-2-1-3-7(8)10/h1-4H,5-6,9H2

Upstream product

• 98491-38-4 3,4-dihydro-2H-benzo[b][1,4]oxazine hydrochloride 
• 5466-88-6 3,4-dihydro-3-oxo-2H-1,4-benzoxazine 
• 7169-34-8 3-oxo-2,3-dihydrobenzo[b]furan 
• 5735-53-5 1,4-benzoxazine 
• 63169-10-8 4-nitroso-3,4-dihydro-2H-benzo[b][1,4]oxazine 

Downstream Products

• 1576240-08-8 (6bS, 11aS)-4-(1,2,6b,7,8,10,11,11a-octahydro-9H-azepino[4,5-b][1,4]oxazino[2,3,4-hi]indol-9-yl)-1-(4-fluorophenyl)-1-butanone 

Relevant articles and documents

ANTHELMINTIC HETEROCYCLIC COMPOUNDS

This invention provides for compounds of the formula (I): wherein the variables are defined herein, or salt thereof, compositions comprising these compounds, and method for the treatment, control or prevention of a parasitic infestation or infection in an animal in need thereof by administering an effective amount of these compounds to said animal.

TRICYCLIC INDOLE MCL-1 INHIBITORS AND USES THEREOF

The present invention provides for compounds that inhibit the activity of an anti-apoptotic Bcl-2 family member Myeloid cell leukemia-1 (Mcl-1) protein. The present invention also provides for pharmaceutical compositions as well as methods for using compounds for treatment of diseases and conditions (e.g., cancer) characterized by the over-expression or dysregulation of Mcl-1 protein.

Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders

We report the synthesis and structure-activity relationships of a class of tetracyclic butyrophenones that exhibit potent binding affinities to serotonin 5-HT2A and dopamine D2 receptors. This work has led to the discovery of 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl) -1-(4-fluorophenyl)-butan-1-one 4-methylbenzenesulfonate (ITI-007), which is a potent 5-HT2A antagonist, postsynaptic D2 antagonist, and inhibitor of serotonin transporter. This multifunctional drug candidate is orally bioavailable and exhibits good antipsychotic efficacy in vivo. Currently, this investigational new drug is under clinical development for the treatment of neuropsychiatric and neurological disorders.